1
|
Na W, Lee SH, Lee S, Kim JS, Han SY, Kim YM, Kwon M, Song YS. Refining of cancer-specific genes in microsatellite-unstable colon and endometrial cancers using modified partial least square discriminant analysis. Medicine (Baltimore) 2024; 103:e41134. [PMID: 39969322 PMCID: PMC11688066 DOI: 10.1097/md.0000000000041134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2024] [Accepted: 12/11/2024] [Indexed: 02/20/2025] Open
Abstract
Despite similarities in microsatellite instability (MSI) between colon and endometrial cancer, there are many clinically important organ-specific features. The molecular differences between these 2 MSI cancers are underexplored because the usual differentially expressed gene analysis yields too many noncancer-specific normally expressed genes. We aimed to identify cancer-specific genes in MSI colorectal adenocarcinoma (CRC) and MSI endometrial carcinoma (ECs) using a modified partial least squares discriminant analysis. We obtained a list of cancer-specific genes in MSI CRC and EC by taking the intersection of the genes obtained from tumor samples and normal samples. Specifically, we obtained publically available 1319 RNA sequencing data consisting of MSI CRCs, MSI ECs, normal colon including the rectum, and normal endometrium from The Cancer Genome Atlas and genome-tissue expression sites. To reduce gene-centric dimensions, we retained only 3924 genes from the original data by performing the usual differentially expressed gene screening for tumor samples using DESeq2. The usual partial least squares discriminant analysis was performed for tumor samples, producing 625 genes, whereas for normal samples, projection vectors with zero covariance were sampled, their weights were square-summed, and genes with sufficiently high values were selected. Gene ontology (GO) term enrichment, protein-protein interaction, and survival analyses were performed for functional and clinical validation. We identified 30 cancer-specific normal-invariant genes, including Zic family members (ZIC1, ZIC4, and ZIC5), DPPA2, PRSS56, ELF5, and FGF18, most of which were cancer-associated genes. Although no statistically significant GO terms were identified in the GO term enrichment analysis, cell differentiation was observed as potentially significant. In the protein-protein interaction analysis, 17 of the 30 genes had at least one connection, and when first-degree neighbors were added to the network, many cancer-related pathways, including MAPK, Ras, and PI3K-Akt, were enriched. In the survival analysis, 16 genes showed statistically significant differences between the lower and higher expression groups (3 in CRCs and 15 ECs). We developed a novel approach for selecting cancer-specific normal-invariant genes from relevant gene expression data. Although we believe that tissue-specific reactivation of embryonic genes might explain the cancer-specific differences of MSI CRC and EC, further studies are needed for validation.
Collapse
Affiliation(s)
- Woong Na
- Department of Pathology, H Plus Yangji Hospital, Seoul, South Korea
| | - Sung Hak Lee
- Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, South Korea
| | - Seunghee Lee
- KYMERA (Konyang Medical Data Research Group), Konyang University Hospital, Daejeon, South Korea
| | - Jong-Seok Kim
- Myunggok Medical Research Center (Institute), College of Medicine, Konyang University, Daejeon, South Korea
| | - Seung Yun Han
- Department of Anatomy, College of Medicine, Konyang University, Daejeon, South Korea
| | - Yong Min Kim
- Department of Pathology, College of Medicine, Konyang University, Daejeon, South Korea
| | - Mihye Kwon
- Department of Internal Medicine, College of Medicine, Konyang University, Daejeon, South Korea
| | - Young Soo Song
- Myunggok Medical Research Center (Institute), College of Medicine, Konyang University, Daejeon, South Korea
- Department of Pathology, College of Medicine, Konyang University, Daejeon, South Korea
| |
Collapse
|
2
|
Wang T, Jin Y, Wang M, Chen B, Sun J, Zhang J, Yang H, Deng X, Cao X, Wang L, Tang Y. SALL4 in gastrointestinal tract cancers: upstream and downstream regulatory mechanisms. Mol Med 2024; 30:46. [PMID: 38584262 PMCID: PMC11000312 DOI: 10.1186/s10020-024-00812-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Accepted: 03/20/2024] [Indexed: 04/09/2024] Open
Abstract
Effective therapeutic targets and early diagnosis are major challenges in the treatment of gastrointestinal tract (GIT) cancers. SALL4 is a well-known transcription factor that is involved in organogenesis during embryonic development. Previous studies have revealed that SALL4 regulates cell proliferation, survival, and migration and maintains stem cell function in mature cells. Additionally, SALL4 overexpression is associated with tumorigenesis. Despite its characterization as a biomarker in various cancers, the role of SALL4 in GIT cancers and the underlying mechanisms are unclear. We describe the functions of SALL4 in GIT cancers and discuss its upstream/downstream genes and pathways associated with each cancer. We also consider the possibility of targeting these genes or pathways as potential therapeutic options for GIT cancers.
Collapse
Affiliation(s)
- Tairan Wang
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, 453003, China
| | - Yan Jin
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, 453003, China
| | - Mengyao Wang
- First Clinical Medical College, Xinxiang Medical University, Xinxiang, 453003, China
| | - Boya Chen
- First Clinical Medical College, Xinxiang Medical University, Xinxiang, 453003, China
| | - Jinyu Sun
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, 453003, China
| | - Jiaying Zhang
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, 453003, China
| | - Hui Yang
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, 453003, China
| | - Xinyao Deng
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, 453003, China
| | - Xingyue Cao
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, 453003, China
| | - Lidong Wang
- State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key, Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou, 450052, China.
| | - Yuanyuan Tang
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, 453003, China.
| |
Collapse
|
3
|
Glancy E, Choy N, Eckersley-Maslin MA. Bivalent chromatin: a developmental balancing act tipped in cancer. Biochem Soc Trans 2024; 52:217-229. [PMID: 38385532 PMCID: PMC10903468 DOI: 10.1042/bst20230426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2023] [Revised: 02/05/2024] [Accepted: 02/07/2024] [Indexed: 02/23/2024]
Abstract
Bivalent chromatin is defined by the co-occurrence of otherwise opposing H3K4me3 and H3K27me3 modifications and is typically located at unmethylated promoters of lowly transcribed genes. In embryonic stem cells, bivalent chromatin has been proposed to poise developmental genes for future activation, silencing or stable repression upon lineage commitment. Normally, bivalent chromatin is kept in tight balance in cells, in part through the activity of the MLL/COMPASS-like and Polycomb repressive complexes that deposit the H3K4me3 and H3K27me3 modifications, respectively, but also emerging novel regulators including DPPA2/4, QSER1, BEND3, TET1 and METTL14. In cancers, both the deregulation of existing domains and the creation of de novo bivalent states is associated with either the activation or silencing of transcriptional programmes. This may facilitate diverse aspects of cancer pathology including epithelial-to-mesenchymal plasticity, chemoresistance and immune evasion. Here, we review current methods for detecting bivalent chromatin and discuss the factors involved in the formation and fine-tuning of bivalent domains. Finally, we examine how the deregulation of chromatin bivalency in the context of cancer could facilitate and/or reflect cancer cell adaptation. We propose a model in which bivalent chromatin represents a dynamic balance between otherwise opposing states, where the underlying DNA sequence is primed for the future activation or repression. Shifting this balance in any direction disrupts the tight equilibrium and tips cells into an altered epigenetic and phenotypic space, facilitating both developmental and cancer processes.
Collapse
Affiliation(s)
- Eleanor Glancy
- Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria 3010, Australia
| | - Natalie Choy
- Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria 3010, Australia
| | - Melanie A. Eckersley-Maslin
- Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria 3010, Australia
- Department of Anatomy and Physiology, The University of Melbourne, Melbourne, Victoria 3010, Australia
| |
Collapse
|
4
|
Klein RH, Knoepfler PS. DPPA2, DPPA4, and other DPPA factor epigenomic functions in cell fate and cancer. Stem Cell Reports 2021; 16:2844-2851. [PMID: 34767751 PMCID: PMC8693620 DOI: 10.1016/j.stemcr.2021.10.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Revised: 10/13/2021] [Accepted: 10/14/2021] [Indexed: 11/30/2022] Open
Abstract
Many gene networks are shared between pluripotent stem cells and cancer; a concept exemplified by several DPPA factors such as DPPA2 and DPPA4, which are highly and selectively expressed in stem cells but also found to be reactivated in cancer. Despite their striking expression pattern, for many years the function of DPPA2 and DPPA4 remained a mystery; knockout of Dppa2 and Dppa4 did not affect pluripotency, but caused lung and skeletal defects late in development, long after Dppa2 and Dppa4 expression had been turned off. A number of recent papers have further clarified and defined the roles of these important factors, identifying roles in priming the chromatin and maintaining developmental competency through regulating both H3K4me3 and H3K27me3 at bivalent chromatin domains, and acting to remodel chromatin and facilitate reprogramming of somatic cells to induced pluripotency. These findings highlight an important regulatory role for DPPA2 and DPPA4 at the transitional boundary between pluripotency and differentiation and may have relevance to the functions of DPPA2 and 4 in the context of cancer cells as well.
Collapse
Affiliation(s)
- Rachel Herndon Klein
- Department of Cell Biology and Human Anatomy, University of California, Davis, CA 95616, USA; Institute of Pediatric Regenerative Medicine, Shriners Hospital for Children Northern California, Sacramento, CA 95817, USA; Genome Center, University of California, Davis, CA 95616, USA
| | - Paul S Knoepfler
- Department of Cell Biology and Human Anatomy, University of California, Davis, CA 95616, USA; Institute of Pediatric Regenerative Medicine, Shriners Hospital for Children Northern California, Sacramento, CA 95817, USA; Genome Center, University of California, Davis, CA 95616, USA.
| |
Collapse
|
5
|
Keeping your options open: insights from Dppa2/4 into how epigenetic priming factors promote cell plasticity. Biochem Soc Trans 2021; 48:2891-2902. [PMID: 33336687 PMCID: PMC7752079 DOI: 10.1042/bst20200873] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Revised: 12/01/2020] [Accepted: 12/02/2020] [Indexed: 12/12/2022]
Abstract
The concept of cellular plasticity is particularly apt in early embryonic development, where there is a tug-of-war between the stability and flexibility of cell identity. This balance is controlled in part through epigenetic mechanisms. Epigenetic plasticity dictates how malleable cells are to change by adjusting the potential to initiate new transcriptional programmes. The higher the plasticity of a cell, the more readily it can adapt and change its identity in response to external stimuli such as differentiation cues. Epigenetic plasticity is regulated in part through the action of epigenetic priming factors which establish this permissive epigenetic landscape at genomic regulatory elements to enable future transcriptional changes. Recent studies on the DNA binding proteins Developmental Pluripotency Associated 2 and 4 (Dppa2/4) support their roles as epigenetic priming factors in facilitating cell fate transitions. Here, using Dppa2/4 as a case study, the concept of epigenetic plasticity and molecular mechanism of epigenetic priming factors will be explored. Understanding how epigenetic priming factors function is key not only to improve our understanding of the tight control of development, but also to give insights into how this goes awry in diseases of cell identity, such as cancer.
Collapse
|
6
|
Wang J, Zhuang H, Zhang H, Li Q, Cao X, Lin Z, Lin T, Chen X, Ni X, Yang J, Zhao Y, Shen L, Wang H, Zhu J, Ye M, Jin X. SPOP suppresses testicular germ cell tumors progression through ubiquitination and degradation of DPPA2. Biochem Biophys Res Commun 2021; 557:55-61. [PMID: 33862460 DOI: 10.1016/j.bbrc.2021.04.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Accepted: 04/01/2021] [Indexed: 10/21/2022]
Abstract
Dysregulation of the ubiquitin-proteasome pathway is strongly associated with cancer initiation and progression. Speckle-type POZ(pox virus and zinc finger protein) protein(SPOP) is an adapter protein of CUL3-based E3 ubiquitin ligase complexes. Gene expression profiling from the Cancer Genome Atlas (TCGA) suggests that SPOP is downregulated in testicular germ cell tumors (TGCTs), but the specific contribution of this protein remains to be explored. In this study, we show that the germ line-specific factor DPPA2 was identified as a proteolytic substrate for the SPOP-CUL3-RBX1 E3 ubiquitin-ligase complex. SPOP specifically binds to a SPOP-binding consensus (SBC) degron located in DPPA2 and targets DPPA2 for degradation via the ubiquitin-proteasome pathway. SPOP downregulation increases the expression of pluripotency markers OCT4 and Nanog but decreases that of early differentiation marker gene Fst. This effect is partly dependent on its activity toward DPPA2. In addition, the dysregulation of SPOP-DPPA2 axis contributes to the malignant transformation phenotypes of TGCT cells.
Collapse
Affiliation(s)
- Jian Wang
- The Affiliated Hospital of Medical School, Ningbo University, Ningbo, 315020, China; Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, 315211, China
| | - Hui Zhuang
- The Affiliated Hospital of Medical School, Ningbo University, Ningbo, 315020, China; Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, 315211, China
| | - Hui Zhang
- The Affiliated Hospital of Medical School, Ningbo University, Ningbo, 315020, China; Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, 315211, China
| | - Qian Li
- The Affiliated Hospital of Medical School, Ningbo University, Ningbo, 315020, China; Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, 315211, China
| | - Xinyi Cao
- The Affiliated Hospital of Medical School, Ningbo University, Ningbo, 315020, China; Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, 315211, China
| | - Zihan Lin
- The Affiliated Hospital of Medical School, Ningbo University, Ningbo, 315020, China; Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, 315211, China
| | - Ting Lin
- The Affiliated Hospital of Medical School, Ningbo University, Ningbo, 315020, China; Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, 315211, China
| | - Xiwei Chen
- The Affiliated Hospital of Medical School, Ningbo University, Ningbo, 315020, China; Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, 315211, China
| | - Xiaoqi Ni
- The Affiliated Hospital of Medical School, Ningbo University, Ningbo, 315020, China; Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, 315211, China
| | - Jianye Yang
- The Affiliated Hospital of Medical School, Ningbo University, Ningbo, 315020, China; Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, 315211, China
| | - Yiting Zhao
- The Affiliated Hospital of Medical School, Ningbo University, Ningbo, 315020, China; Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, 315211, China
| | - Liliang Shen
- Department of Urology, Yinzhou Renmin Hospital Affiliated to Medical School of Ningbo University, Ningbo, 315040, China
| | - Haibiao Wang
- Department of Hepato-biliary-pancreatic Surgery, The Affiliated Ningbo Medical Center of LiHuiLi Hospital of Medical School of Ningbo University, Ningbo, 315048, China
| | - Jie Zhu
- Department of Hepato-biliary-pancreatic Surgery, The Affiliated Ningbo Medical Center of LiHuiLi Hospital of Medical School of Ningbo University, Ningbo, 315048, China
| | - Meng Ye
- The Affiliated Hospital of Medical School, Ningbo University, Ningbo, 315020, China; Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, 315211, China
| | - Xiaofeng Jin
- The Affiliated Hospital of Medical School, Ningbo University, Ningbo, 315020, China; Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, 315211, China.
| |
Collapse
|
7
|
Soleymani S, Khales SA, Jafarian AH, Kalat HR, Forghanifard MM. PYGO2 as an independent diagnostic marker expressed in a majority of colorectal cancers. J Histotechnol 2019; 42:98-103. [PMID: 31492088 DOI: 10.1080/01478885.2019.1610214] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Colorectal cancer (CRC) is one of the most common gastrointestinal cancers worldwide. Detection of CRC at the early stages of disease can play an important role in decrease of associated mortality rates. The Wnt signaling pathway is crucial for the progression of different cellular and developmental processes and Wnt pathway deregulation has been well characterized in a variety of cancers, particularly in CRC. The aim of this study was to analyze protein expression of Pygopus2 (PYGO2), the main transcription factor of Wnt pathway, in CRC tissues and evaluate its probable correlation with clinicopathological features of the patients. The expression pattern of PYGO2 was evaluated by immunohistochemistry in tumor tissues and their margin normal which is the piece of normal, or unaffected tissue excised from the surrounding the visible tumors in 46 CRC patients. A defined scoring system was applied to analyze immunostaining results. The expression of PYGO2 protein was detected in all tumor tissues. Furthermore, this expression was significantly higher in CRC samples than in normal tissues. There was a significant association between PYGO2 protein expression in CRC and tumor cell metastasis to the lymph nodes. Considering the significant expression of PYGO2 protein in colorectal tumor cells and its correlation with lymph node metastasis, this protein may be used as a biomarker for metastatic CRC as well as a putative therapeutic target to inhibit aggressiveness and metastasis of CRC.
Collapse
Affiliation(s)
- Sedigheh Soleymani
- Department of Biology, Damghan Branch, Islamic Azad University , Damghan , Iran
| | - Sima Ardalan Khales
- Immunology Research Center, Mashhad University of Medical Sciences , Mashhad , Iran
| | - Amir Hossein Jafarian
- Department of Pathology, Ghaem Hospital, Mashhad University of Medical Sciences , Mashhad , Iran
| | | | | |
Collapse
|
8
|
Abstract
PURPOSE Evading apoptosis is one of the major hallmarks of cancer cells. Inhibitors of apoptosis (IAPs) proteins are considered as a most important gene families involved in apoptosis. BRUCE protein, a member of IAPs, is able to quench apoptosis as well as playing role in cell division. Our aim in this study was to analyze BRUCE protein expression in gastric carcinoma (GC) and its correlation with the clinicopathological features. METHODS Using immunohistochemistry, 52 GC specimens were studied for BRUCE protein expression. A validated scoring method was applied. RESULTS BRUCE protein expression was detected in majority of tumor tissues (98.07 %). A significant correlation between gender and BRUCE expression (p = 0.024) was detected. Indeed, females showed higher level of BRUCE expression than male patients. CONCLUSION Since specific expression of BRUCE protein was revealed in majority of GC tissues, BRUCE protein may be a useful therapeutic target for cancer therapy. Furthermore, based on the native role of BRUCE protein in inhibition of apoptosis, using this protein in targeted therapy of tumor cells may help to inhibit tumor cells growth and survival leading to rapid elimination of tumor mass.
Collapse
|
9
|
Hashemi Bidokhti M, Abbaszadegan MR, Sharifi N, Abbasi Sani S, Forghanifard MM. Contribution of MAML1 in esophageal squamous cell carcinoma tumorigenesis. Ann Diagn Pathol 2017; 27:79-82. [PMID: 28325367 DOI: 10.1016/j.anndiagpath.2017.01.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2016] [Revised: 01/14/2017] [Accepted: 01/29/2017] [Indexed: 12/26/2022]
Abstract
BACKGROUND Notch signaling pathway is involved in different cellular and developmental processes including cell proliferation, differentiation and apoptosis. Mastermind like1 (MAML1) is a critical key transcription coactivator of this pathway. In this study, we aimed to examine MAML1 protein expression in esophageal squamous cell carcinoma (ESCC) and reveal its association with clinicopathological variables of the patients. METHODS Tumoral and their margin normal tissues from 56 ESCC patients were recruited for protein expression analysis using immunohistochemistry (IHC). Furthermore, MAML1 expression was analyzed in ESCC cell line KYSE-30 using immunocytochemistry. RESULTS Overexpression of MAML1 was detected in 59% of tumor samples. It was significantly associated with different indices of poor prognosis including depth of tumor invasion (P=0.026), grade of tumor differentiation (P=0.002), stage of tumor progression (P=0.004) and sex (P=0.027). CONCLUSION Beside the appearing evidences explaining MAML1 role in different cellular processes and its deviations in different malignancies and also based on its correlation with different clinicopathological variables of ESCC, MAML1 can be proposed as potentially novel molecular marker for ESCC progression and tumorigenesis as well as therapeutic target to inhibit and reverse progression and development of the disease.
Collapse
Affiliation(s)
- Mahnaz Hashemi Bidokhti
- Department of Biology, Damghan branch, Islamic Azad University, Damghan, Iran.; Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
| | - Mohammad Reza Abbaszadegan
- Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
| | - Noorieh Sharifi
- Department of Pathology, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
| | - Soodabeh Abbasi Sani
- Department of Biology, Damghan branch, Islamic Azad University, Damghan, Iran.; Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
| | | |
Collapse
|